drugset / Trial / NCT04974749
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
NaSingle-groupOpen-labelTreatment
Summary
The main aim of the study is to assess the safety of REPLAGAL. Study participants will receive REPLAGAL as an intravenous infusion every other week for 52 weeks. Participants will visit their study clinic many times throughout the study.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2024-01-03
- Completion
- 2024-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Replagal | Protein / enzyme biologic | 0.2 mg/kg | Intravenous |